The Association of British Pharmaceutical Industry (ABPI) welcomes the strong focus on science and innovation in the Government's green paper on Industrial Strategy, set out today by the Prime Minister. This is further demonstration of their support for research and development which is a...
Following publication of ‘The United Kingdom’s Exit from, and New Partnership with, the European Union’ White Paper, the Association of the British Pharmaceutical Industry (ABPI) has issued the following statement.
The Association of the British Pharmaceutical Industry (ABPI) has responded to today’s triggering of Article 50 of the Lisbon Treaty by Prime Minister Theresa May, officially starting the process of the United Kingdom (UK) negotiating its departure from the European Union (EU).
This week, the House of Lords Science and Technology Committee published a report into the Life Sciences Industrial Strategy, asking: "Who's Driving the Bus?"
This week, the Kings Fund published a new report into the cost of medicines looking at how much the health service spends in total on medicines; both generics and branded medicines.
What will the future of medicine look like? A new virtual reality experience from the Association of the British Pharmaceutical Industry explores futuristic treatments and technologies like inhalable nanobots and 3D printed medicine patches, already being researched by companies and which rival Sci-...
Statement from the Association of the British Pharmaceutical Industry (ABPI) on the European Union referendum result.
Dr Virginia Acha, ABPI's Executive Director of Research, Medical and Innovation has told MPs on the Exiting the European Union (EU) Committee that for the UK pharmaceutical industry a primary objective for Government in Brexit negotiations should be to secure alignment and cooperation with EU...
The Association of the British Pharmaceutical Industry (ABPI) has responded to today's publication of the Exiting the EU Committee report into the process for exiting the European Union and the Government's negotiating objectives.
The new Government must be more ambitious in securing a world-class NHS for patients and should seek to improve access to medicines in line with other developed nations.
Following news that an announcement regarding the future location of the European Medicines Agency (EMA) will be delayed until the European Commission's General Affairs Council in November 2017, the Association of the British Pharmaceutical Industry (ABPI) have issued the following statement.